Introduction
Tumor angiogenesis constitutes a pre-requisition for progressive tumor disease and angiogenic factors like vascular endothelial growth factor (VEGF) correlate to tumor vascularization in a variety of tumor entities, including colorectal cancer (CRC). 1 Subsequently, antiangiogenic treatments reached clinical application; for example, the monoclonal chimerical VEGF antibody bevazucimab has been approved for application in colorectal carcinoma disease in patients. 2, 3 Among the angiogenic factors, VEGF ranks as key factor and particularly VEGF-A is considered to be the most relevant promoter of (tumor) angiogenesis. Apart from VEGF-A, the VEGF family embraces VEGF-B, -C and -D. The VEGF-A splice variants VEGF 121 and VEGF 165 bind with high affinity to the VEGF-receptor 2 (VEGFR-2, human/murine KDR/Flk-1), which has been recognized to mainly mediate angiogenic VEGF functions. Vascular endothelial growth factor isoforms bind -with some specific preference -to one of the three VEGFRs: VEGFR-1 (Flt-1), VEGFR-2 (Flk-1/KDR) and VEGFR-3 (Flt1-4), all of which are members of the class III receptor-type tyrosine kinase receptor family. 4, 5 Several experimental studies have clearly demonstrated that blocking of the VEGF signal pathway presents an effective mean to inhibit tumor growth. Gene delivery of a dominant-negative soluble fragment of FLK-1 (sFlk-1) has been shown to inhibit experimental fibrosarcoma, lung carcinoma, melanoma, pancreatic and prostate cancer growth. [6] [7] [8] In one of our previous study, we were able to show that VEGF inhibition reduced effectively metastatic and orthotopic hepatocellular carcinomas. 9 The underlying antitumor mechanism of sFlk-1 secretion is that the secreted Flk-1 fragment sequesters circulating VEGF and subsequently forms VEGFR heterodimers without the activation of the receptor-type tyrosine kinase. [6] [7] [8] Recently, Bocci et al. 10 employed a similar approach. They observed that the systemic application of an anti-VEGFR-2 antibody (DC101) induced increased plasma VEGF levels not only in tumor-bearing but also in tumor-free mice and that the noted VEGF upraise was dose dependent. Vascular endothelial growth factor serum concentrations correlated to the biological antitumor response in this latter study. Although VEGF inhibition by gene transfer methods has also been effectively applied to control experimental tumor growth, effects on systemic VEGF levels and correlation to antitumor response have not yet been investigated. Therefore, we evaluated the effect of VEGF inhibition by adenoviral-mediated gene delivery of a sFlk-1 on systemic VEGF levels, organ-specific VEGF-RNA expression and antitumor efficacy in a murine CRC model.
Results

Propagation of adenoviral vectors and transgene expression
Construction of adenoviruses encoding for AdLacZ and AdsFlk-1 had been described elsewhere. Viruses were propagated according to standard procedures. Optical particle units ranged around 2 Â 10 12 optical particle units (OPU)/ml for AdLacZ and 8 Â 10 12 OPU/ml for AdsFlk-1. Analysis of the plaque assays showed a concentration of infectious adenovirus of 1 Â 10 12 plaque forming unit (PFU)/ml for AdLacZ and 8 Â 10 11 PFU/ml for AdsFlk-1. sFlk-1 protein was detected in 5 ml serum of AdsFlk-1-treated mice only over a time period of 56 days, whereas no band was detected in AdLacZ-treated mice ( Figure 1 ).
VEGF concentration in cell supernatant, serum, and liver and VEGF-mRNA organ and liver sinusoidal endothelial cells' expression As we applied an anti-VEGF treatment using AdsFlk-1 to two metastatic CRC tumor models, we initially ensured that this tumor cell line actually secreted VEGF to cell supernatant. We found that conditioned cell culture medium (CM) of CT26 cells (10 5 /well) contained VEGF at considerable concentrations of about 360 pg/ml (VEGF concentration in other cell lines: liver sinusoidal cells 1 pg/ml (background levels); Hepa1-6 hepatoma cells 197 pg/ml, Hepa129 hepatoma cells 15 pg/ml). However, when serum of mice bearing subcutaneous tumors was checked for circulating VEGF, no VEGF upraise was detected as compared to non-tumor-bearing mice. Consecutively, no correlation between tumor burden and VEGF concentration could be found. Vascular endothelial growth factor remained at background levels of about mean 30 fg/mg serum protein in tumor-bearing mice.
To investigate possible feedback mechanisms induced by the anti-VEGF treatment, VEGF was also measured in AdsFlk-1-and AdLacZ-treated tumor-bearing mice. Interestingly, a significant VEGF upraise from background levels was found in the AdsFlk-1 group but not in the AdLacZ control, showing a 5.6-fold increase in the AdsFlk-1-treated animals as compared to the control, reaching 230 fg/mg serum protein (or 391 pg/ml serum) in the AdsFlk-1 treatment group as compared to 41 fg/mg serum protein (or 70 pg/ml) in the AdLacZ control (P ¼ 0.026, Figure 2a ) already on day 3. At 2 weeks after vector injection, VEGF levels were still 4.1-fold elevated reaching 202 fg/mg serum protein (343 pg/ml serum) in the AdsFlk-1 treatment group as compared to 50 fg/mg serum protein (84 pg/ml) in the AdLacZ control ( Figure  2a ). As CT26 tumor growth itself was shown not to affect VEGF levels, this upraise could be specifically attributed to the AdsFlk-1 treatment.
To prove the tumor-independent effect of AdsFlk-1 administration on VEGF serum concentrations, we also determined VEGF in treated but tumor-free mice. As presumed, AdsFlk-1 increased VEGF in both tumor bearing and healthy mice. Obviously, AdLacZ control had no effects on VEGF (Figure 2b) .
Although it became clear that AdsFlk-1 administration augments systemic VEGF levels, the source of circulating VEGF was yet unclear. Therefore, we checked different organs for VEGF-mRNA by reverse transcription (RT)-polymerase chain reaction (PCR). Under the conditions chosen, VEGF-RNA was detected in the liver, kidney, lung, spleen and foregut ( Figure 3 ). As systemic injection of recombinant adenoviruses mainly transduces liver tissue, it was intriguing to additionally measure VEGF protein concentrations in liver tissue. Collectively, the data show that the relative and absolute hepatic VEGF incline considerably exceeded the corresponding serum values (Figure 4 ). On day 3, VEGF concentrations were 16.5-fold increased in the AdsFlk-1-treated mice (5218 fg/mg protein) compared to the AdLacZ control (315 fg/mg protein, P ¼ 0.04). On day 19, the intrahepatic VEGF concentration had a level of 3311 fg/mg protein (P ¼ 0.002). Although we could not completely exclude other origins of VEGF, the liver had to be acknowledged as a major source of VEGF in this setting.
Therefore, we decided to further support the hypothesis of liver-based VEGF generation by reversing hepatic VEGF expression by gene silencing. For this purpose, small interfering RNA (siRNA)-VEGF, specifically targeted against VEGF, and nonsense siRNA-control were administered into tumor-bearing mice that had also Figure 1 Transgene expression of AdsFlk-1 in vivo. AdsFlk-1 and AdLacZ (10 10 PFU/mouse) were intravenously administered and serum samples were harvested at different time points. Serum (10 ml) was separated on a 7.5% sodium dodecyl sulfate (SDS)-polyacrylamide gel and sFlk-1 was immunostained on a polyvinylidene fluoride (PVDF) membrane. Abundant transgene expression was detectable in mice that had received AdsFlk-1, whereas no corresponding band could be found in the AdLacZ control.
Anti-VEGF treatment induced VEGF increase V Schmitz et al received AdsFlk-1 or AdLacZ. Before, VEGF upregulation had been verified in these animals. Vascular endothelial growth factor serum levels were reduced by 72% (P ¼ 0.033) and 81% (P ¼ 0.026) in the AdsFlk-1/ siRNA-VEGF compared to the siRNA control 14 and 18 days after siRNA injection ( Figure 5a ). On day 42 after siRNA injection, all mice were killed. Vascular endothelial growth factor was still elevated in the siRNAcontrol group (325 fg/mg) compared to normalized values in the siRNA-VEGF group (21 fg/mg). The systemic VEGF reduction was paralleled by a decline in intrahepatic VEGF levels down to 692 fg/mg protein in the siRNA-VEGF group compared to 1300 fg/ml in the siRNA-control group.
Two main intrahepatic cell types, hepatocytes and liver sinusoidal endothelial cells (LSEC), may encounter for hepatic VEGF generation. To distinguish between hepatocellular and endothelial VEGF generation, VEGF expression was determined in isolated LSEC, and as seen in Figure 5b , VEGF-RNA was not expressed in LSEC under the chosen conditions ( Figure 5b ). The lack of VEGF-RNA was not influenced by adding different concentrations (30 and 60%) of conditioned cell culture medium, which contained sFlk-1, to LSEC cultures ( Figure 5b ). Corresponding to the complete lack of VEGF-RNA, VEGF protein levels were as low as background levels as determined by enzyme-linked immunosorbent assay (ELISA) in these experiments. In conclusion, LSEC can certainly be excluded as relevant source of hepatic VEGF in this study.
Thus, taken together, we have gathered evidence that substantial amounts of circulating VEGF derived from the liver in this study setting.
Antitumor efficacy of AdsFlk-1 in subcutaneous colorectal cancer
As increased VEGF levels also potentially might interact with antitumor efficacy of AdsFlk-1, we analyzed antitumor efficacy and also correlated tumor size and VEGF concentrations. To address this question, effects of AdsFlk-1 were tested in a subcutaneous metastatic CRC model. CT26 tumor-bearing mice received intravenous vector injections and tumor growth and survival was assessed. Subcutaneous tumor growth was signifi- Figure 3 Organ-specific vascular endothelial growth factor (VEGF)-RNA expression. Healthy, tumor-free mice were treated with AdsFlk-1 (n ¼ 4) or AdLacZ (n ¼ 4; 5 Â 10 9 PFU/mouse) and organ samples were harvested 3 days after vector application. RNA was extracted for reverse transcription (RT)-polymerase chain reaction (PCR) using specific primers for VEGF. C, control; 1, lung; 2, foregut; 3, spleen; 4, kidney; L, ladder; 5, liver (c1-c5, control animals; 1-5, AdsFlk-1-treated mice). 9 PFU/mouse) and serum samples were taken at different time points after treatment initiation. (b) Healthy, tumor-free mice were treated with AdsFlk-1 (n ¼ 4) or AdLacZ (n ¼ 4; 5 Â 10 9 PFU/mouse) and serum samples were taken 3 days after vector application. Vascular endothelial growth factor protein was quantified by enzyme-linked immunosirbent assay (ELISA) technique in 20 ml serum (n ¼ 3). Data are given as mean with s.e.m., *Po0.05.
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V Schmitz et al cantly inhibited and survival improved in the AdsFlk-1 treatment group as compared to the control ( Figure 6 ). The mean survival period was increased in the AdsFlk-1 group compared to the control (28 days vs 18 days, *Po0.016). Taking into account the recent data regarding the value of VEGF concentrations as surrogate marker for antitumor treatment efficacy, we further analyzed the correlation between individual tumor sizes and corresponding VEGF concentrations. As seen in Figure 7 , no significant correlation could be recognized in our study (Pearson's test P ¼ 0.13, r ¼ À0.4).
In vivo testing of antiangiogenic effects (Matrigel angiogenesis assay)
Antitumor effects could most probably be attributed to angiostatic effects. In a previous study, we already had demonstrated angiostatic potency of systemic AdsFlk-1 application in another tumor model and in a Matrigel plug assay in vivo. Then, the intravenous administration of AdsFlk-1 had resulted in significant 80% inhibition of VEGF-stimulated vessel formation in subcutaneous matrigel plugs as compared to the AdLacZ control in Balb/c mice.
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Discussion
Vascular endothelial growth factor has a requisite role in promoting progressive tumor growth mediated by tumor angiogenesis and, accordingly, the adenoviral-mediated gene transfer of an inhibitory VEGFR-2 fragment (sFlk-1) has been demonstrated to form an effective approach to control experimental tumor growth. [6] [7] [8] To our knowledge, it is unclear to date whether VEGF inhibition by adenoviral-mediated gene transfer affects systemic VEGF levels in vivo. As this VEGF upregulation might interfere with antitumor treatment responsiveness, we addressed this question by determining VEGF protein levels and organ-specific VEGF-mRNA expression after systemic VEGF inhibition. For this purpose, an adeno- , AdLacZ (n ¼ 12) and AdsFlk-1 (n ¼ 11) were intravenously administered (5 Â 10 9 PFU/animal resuspended in 150 ml 0.9% NaCl). A mean tumor diameter of 15 mm was defined as endpoint and considered to reflect survival. Data are given as mean with s.e.m., *Po0.05. Figure 5 (a) Effective reduction of serum vascular endothelial growth factor (VEGF) levels by small interfering RNA (siRNA)-VEGF injection. Tumor-bearing mice were treated with AdsFlk-1 (n ¼ 3) or AdLacZ (n ¼ 2; 5 Â 10 9 PFU/mouse). Small interfering RNA -VEGF or siRNA-control were intravenously injected and serum samples were taken 14 days after siRNA injection. Serum samples were taken 3 days after vector application. Vascular endothelial growth factor protein was quantified by enzyme-linked immunosorbent assay (ELISA) technique in 20 ml serum. Data are given as mean with s.e.m., *Po0.05. (b) Liver sinusoidal endothelial cells (LSEC) were isolated from whole murine livers and cultivated for 2 days on collagen-coated culture dishes. Liver sinusoidal endothelial cells were incubated for 36 h with 0, 30 or 60% conditioned culture medium. Cells were harvested and RNA was isolated and reverse transcribed. Polymerase chain reaction was performed with specific primers for murine b-actin as control (lanes 1-5) and murine VEGF (lanes 1a-5a). L, ladder; 1, control; 2, 30% AdLacZ; 3, 60% AdLacZ; 4, 30% AdsFlk-1; 5, 60% AdsFlk.
Anti-VEGF treatment induced VEGF increase V Schmitz et al virus encoding an antagonistically acting Flk-1 fragment was applied to tumor-free and CRC tumor-bearing mice. Interestingly, injection of AdsFlk-1 into tumor-free and tumor-bearing mice resulted in similar upregulation of systemic VEGF levels. To narrow down the source of VEGF secretion, we checked different organs for VEGF-mRNA expression by RT-PCR, but could not detect relevant changes regarding the kidney, lung, foregut, spleen and liver. As our approach using recombinant adenoviruses, that mainly leads to hepatic transduction, and VEGF upraise clearly was independent of tumor burden, we hypothesised that hepatic VEGF generation might be revertible by gene silencing. And indeed, systemic application of siRNA-VEGF was able to almost normalize VEGF serum levels in AdsFlk-1-treated mice. This finding further supports the hypothesis that the liver presents a main source of circulating VEGF induced by adenoviral gene delivery of sFlk-1. Despite these increased systemic VEGF concentrations, significant antitumor effects were maintained as shown in a metastatic subcutaneous colorectal carcinoma model.
It has been described that secretion of sFlk-1 by gene delivery acts via two complementary mechanisms: sequestration of circulating VEGF and inhibition of VEGFR-2 activation by forming non-receptor-activating VEGF-sFlk-1 heterodimers. Thus, the underlying anti-VEGF mechanism differs from receptor antibody studies in which VEGF and the antibody compete for ligation to the corresponding VEGF receptor. There is a recent study that was published during the preparation of our manuscript, by Bocci et al. 10 showing that systemic VEGF levels were increased owing to treatment with the specific VEGFR-2 antibodies DC101 and RAFL-1. On the contrary, the synthetic small molecule antagonists of VEGFR-2, PTK787 and SU5416 did not affect VEGF levels in that study. Interestingly, this group also detected VEGF upraise in both tumor-free and tumor-bearing mice.
Although the AdsFlk-1 vector construct had been used successfully in different tumor models before, the impact on systemic VEGF levels was not been addressed in these previous studies. [6] [7] [8] Although CT26 tumor cells secreted considerable amounts of VEGF protein into cell supernatant, tumor burden did not affect systemic VEGF levels in vivo in Balb/c mice in our study. Thus, together with our data, it can be concluded that the tumor itself is not an essential source of elevated systemic, circulating VEGF. This is a striking finding, as increased intratumoral VEGF generation by the tumor itself might have presented a possible mechanism to escape angiostatic effects of an anti-VEGF treatment and, noteworthy, we also did not reveal elevated intratumoral VEGFmRNA levels in another study. 9 Previous data by Bocci et al. suggested that determination of VEGF presents a suitable biochemical surrogate marker for antitumor response. However, in our study -applying a similar but still different therapy -no significant correlation between individual VEGF concentrations and tumor sizes could be identified.
Among the different organs, such as the lung, kidney, foregut and spleen, considerable VEGF expression was detectable in liver samples. To indirectly confirm the role of the liver as VEGF source, we aimed to inhibit liverbased VEGF production by siRNA-VEGF injection, because systemic injection of naked DNA and siRNA had been described to be capable of specifically inhibiting the expression of the targeted gene even for a prolonged time period. [11] [12] [13] [14] [15] And indeed, the AdsFlk-1-induced VEGF increase was almost reverted to normal levels in serum and markedly reduced in liver homogenates, only in the siRNA-VEGF-but not in the siRNAcontrol-treated mice. To distinguish hepatocellular and endothelial VEGF generation, we additionally isolated LSEC to detect (RNA-)VEGF, but no VEGF expression was expressed at all. Former studies already had analyzed VEGF tissue distribution under normoxic conditions, showing that the liver physiologically transcribes VEGF. 16, 17 More precisely, a very recent study demonstrated that LSEC lack VEGF expression and that hepatocytes express VEGF in adult mice, supporting our finding. 18 Taken together, these data convincingly excluded LSEC as a source of AdsFlk-1-induced VEGF upraise and substantiated the hypothesis that considerable amounts of circulating VEGF originated from hepatocytes in this model. It has to be mentioned that altered VEGF clearance and metabolism might also contribute to increased VEGF concentrations as discussed by Bocci et al., 10 but the efficient reduction of VEGF concentrations by siRNA-VEGF injection makes this an unlikely reason for the VEGF upraise in this study. Still, there is a broad range of other possible sources that have been discussed to account for the VEGF upraise in a VEGFR-2 antibody study, such as platelets, 19 extracellular matrix, [20] [21] [22] [23] alpha2-macroglobulin 24 or circulating soluble VEGFR-2.
10,25 Although we cannot exclude that some of these potential VEGF sources partially contributed to the VEGF elevation, our data indicate that the hepatocytes substantially participate in regulating VEGF in our study setting. Still, further studies will have to investigate the biological function of VEGF upregula- 9 PFU/animal, see Figure 4 ) and mice were killed at different time points (day 3, 6, 9 and 14 after treatment initiation). Linear correlation was calculated using Pearson's test, r ¼ 0.42; P ¼ 0.13.
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V Schmitz et al tion secondary to an anti-VEGF treatment. With respect to antitumor efficacy, elevated VEGF levels did not seem to compromise antitumoral effects of AdsFlk-1 in this tumor model. Moreover, it will be intriguing to test whether a combined treatment by receptor blockade and VEGF gene silencing is capable of exerting additive antitumor effects. Our data correspond well with previous publications showing strong antitumor effects of anti-VEGF treatments, and obviously, antitumor effects prevail in spite of increased systemic VEGF in this metastatic subcutaneous CRC model. Although, we did not identify undesired side effects of increased VEGF in this experimental study -especially not regarding antitumor efficacy -VEGF concentrations should also be determined in the ongoing anti-VEGF treatment studies.
Materials and methods
Animals and cell lines
Female Balb/c mice (6-10 weeks old) were supplied by Charles River (Bad Sulzfeld, Germany) and kept in the local central animal facility of the university hospital Bonn. The mice were housed under standard conditions and had free access to water and food. Animal procedures were performed in accordance with approved protocols and followed recommendations for proper care and use of laboratory animals.
The 293 cells (embryonic E1 transformed kidney cell line) were obtained from American Type Culture Collection (ATCC) and the murine CT26 colorectal carcinoma cell line was derived by intrarectal injection of N-nitroso-N-methylurethane in a female Balb/c mouse. 26 Cells were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 200 mM glutamine and penicillin/streptomycin.
Isolation of liver sinusoidal endothelial cells
In order to further specify differential VEGF expression, (LSEC) were prepared as described previously. 27 Briefly, LSEC were obtained from murine livers by portal collagenase A perfusion (0.05%) and then liver tissue was mechanically disintegrated and again incubated in collagenase A (Sigma-Aldrich, Taufkirchen, Germany). Liver sinusoidal endothelial cells were concentrated by density gradient centrifugation using a metrizamide (Nycomed, Oslo, Norway) gradient. Liver sinusoidal endothelial cells were harvested from the upper cell layer and resuspended in magnetic-activated cell sorting (MACS) buffer to be mixed with 12 ml LSEC Beads per 1 Â 10 6 cells (Miltenyi Biotech GmbH, Bergisch Gladbach, Germany). Liver sinusoidal endothelial cells were incubated for 20 min at 41C and then transferred to auto-MACS (Miltenyi Biotech GmbH, Bergisch Gladbach, Germany) for separation. Liver sinusoidal endothelial cells were cultured on collagen-coated culture dishes (Sigma-Aldrich, Taufkirchen, Germany) in 10% FBS supplemented with DMEM. Before RNA was extracted from LSEC to characterize RNA-VEGF expression, cells were cultured together with 0, 30 or 60% conditioned culture medium (steming from AdLacZ-or AdsFlk-1-infected cells) for 36 h.
Construction of recombinant adenoviruses encoding a soluble form of Flk-1 and vector propagation
The AdFlk-1 construct was generously provided by Mulligan (Boston, MA, USA); the vector construction has been described elsewhere. 6 Shortly, the construct embraced the Flk-1 cDNA fused to a murine IgG2-a Fc fragment. This Flk-1-Fc fusion gene (sFlk-1) was put under the control of the human cytomegalovirus promoter and the rabbit b-globulin intron and polyadenylation signal. This expression cassette was inserted into the E1-deletion site of the adenovirus type 5 genome and recombinant virus has been generated by transfection into 293 cells.
All recombinant adenoviruses were expanded and purified by double cesium-chloride ultracentrifugation, and constructs were dialyzed against 10 mM Tris/1 mM MgCl 2 . Virus stocks were stored at À801C until further use. Virus titer in stocks was determined by measuring virus particles (OPU/ml) and by cytotoxic plaque assay (PFU/ml) in 293 cells; the resulting OPU/PFU ratios were around 10.
Western blot for sFlk-1 sFlk-1 protein was detected in 10 ml serum of AdLacZ-or AdsFlk-1-treated mice (10 10 PFU/mouse) by Western blot analysis. After protein separation on a 7.5% sodium dodecyl sulfate (SDS)-polyacrylamide gel and transfer to a polyvinylidene fluoride (PVDF) membrane, sFlk-1 was immunostained using a goat anti-mouse VEGFR-2 primary antibody (1:500; R & D Systems, WiesbadenNordenstadt, Germany) and a mouse anti-goat/sheep secondary antibody (1:160 000; Sigma Aldrich, Saint Louis, MO, USA). Recombinant mouse VEGFR-2 protein (200 ng; R & D Systems, Wiesbaden-Nordenstadt, Germany) was used as positive control. The membrane was developed with chemiluminescence kit (SuperSignal West Pico, Perbio, Bonn, Germany) on a CL XPosure film (Perbio, Bonn, Germany).
VEGF mRNA and protein expression
To identify sources of VEGF, VEGF-mRNA expression was determined in LSEC, liver, tumor, lung, heart and kidney samples. Tissues were homogenized and RNA was isolated using the NucleoSpin RNA II Kit (Nucleobond, Dü ren, Germany) according to the manufacturer's protocol. After DNase (Promega, Mannheim, Germany) treatment of 1 mg RNA, RNA was reverse transcribed and followed by PCR using specific VEGF primer pairs: forward primer 
Tumor induction
In vivo antitumoral efficacies were studied in a subcutaneous metastatic CRC tumor model in Balb/c mice. For establishment of subcutaneous tumors, 10 6 CT26 CRC cells were resuspended in 100 ml FCS-free culture medium and subcutaneously injected via a 28 G syringe at the right-hand side.
In vivo antitumor treatment
After reaching a mean tumor volume of 35 mm 3 , AdLacZ (n ¼ 12) and AdsFlk-1 (n ¼ 11) were administered intravenously (5 Â 10 9 PFU/animal resuspended in 150 ml 0.9% NaCl). The tumor growth was monitored by Vernier calliper measurement every 2 days for the first 2 weeks and survival rates were assessed. Tumor volumes (V) were calculated by the formula V ¼ length Â width 2 Â 0.52 and survival times were documented.
In a subgroup of animals, four mice were killed out of each group at days 3, 6, 9 and 14 to harvest organ and blood samples for further examinations (VEGF-ELISA and RT-PCR).
Intravenous siRNA-VEGF injection into tumor-bearing mice
In a subgroup of tumor-bearing mice, the influence of specific siRNA on hepatic VEGF expression was evaluated: siRNA targeted against nucleotide 464-483 of VEGF-A (sense sequence 5 0 -AUGUGAAUGCAGACCA AAGAA-dTdT and antisense sequence 5 0 -UUCUUUGG UCUGCAUUCACAU-dTdT was commercially provided by Dharmacon (Munich, Germany). The siRNA had been selected according to a recent publication. 28 In our study, 3.3 mg/mouse were intravenously injected (by hyperdynamic technique: siRNA was administered in a total of 1.8 ml (aqua ad injectionem) within 10 s injection time into a heat-dilated tail vein (siRNA VEGF n ¼ 3; siRNA control n ¼ 3)). Serum was taken for VEGF determination.
In vivo testing of antiangiogenic effects (Matrigel angiogenesis assay)
Antiangiogenic effects of AdsFlk-1 treatment was demonstrated in a previous study by our group using the in vivo Matrigel assay. Shortly, mice had received AdLacZ or AdsFlk-1 (5 Â 10 9 PFU/animal) and 500 ml of VEGF-embedded Matrigel (20 ng/ml) were subcutaneously implanted into the right mid-abdominal region 1 day later. Mice were killed and plugs were removed to determine endothelial-like cell infiltration (mean cell number/mm 2 7s.e.m.) about 1 week later.
Statistical analysis
Tumor data are given as mean tumor volumes with standard error of the mean (s.e.m.). Differences between tumor volumes of different experimental groups were analyzed for statistical significance by a parametric, two-tailed test (Student's t-test) for unpaired samples. Survival rates are presented as Kaplan-Maier curves and significance was calculated by the log-rank test. Significance of correlation was calculated using Pearson's test. *Po0.05 was considered to be significant.
